Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gene therapy for superficial bladder cancer.

C J Rosser1, W F Benedict, C P Dinney

  • 1Departments of Urology and Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Box 446, 1515 Holcombe Blvd, Houston, TX 77030, USA.

Expert Review of Anticancer Therapy
|July 13, 2002
PubMed
Summary

Gene therapy offers new hope for superficial bladder cancer. Combining polyamides with adenoviral vectors shows significant potential to improve treatment outcomes and may offer an alternative to current therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corrigendum to "Nomogram Predicting Bladder Cancer-specific Mortality After Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-invasive Bladder Cancer: Results of an International Consortium" [Eur Urol Focus 2021;7:1347-54].

European urology focus·2022
Same author

Nomogram Predicting Bladder Cancer-specific Mortality After Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-invasive Bladder Cancer: Results of an International Consortium.

European urology focus·2020
Same author

Concomitant CIS on TURBT does not impact oncological outcomes in patients treated with neoadjuvant or induction chemotherapy followed by radical cystectomy.

World journal of urology·2018
Same author

Angiogenin promotes tumoral growth and angiogenesis by regulating matrix metallopeptidase-2 expression via the ERK1/2 pathway.

Oncogene·2014
Same author

Use of monitoring levels of soluble forms of cytokeratin 18 in the urine of patients with superficial bladder cancer following intravesical Ad-IFNα/Syn3 treatment in a phase l study.

Cancer gene therapy·2014
Same author

Fluid intake, genetic variants of UDP-glucuronosyltransferases, and bladder cancer risk.

British journal of cancer·2013

Area of Science:

  • Oncology
  • Molecular Biology
  • Biotechnology

Background:

  • Superficial bladder cancer requires effective therapeutic strategies.
  • Gene therapy presents a promising avenue for cancer treatment.
  • Optimizing gene delivery is crucial for therapeutic efficacy.

Purpose of the Study:

  • To review the fundamentals of gene therapy for superficial bladder cancer.
  • To discuss strategies for enhancing gene therapy's therapeutic effects.
  • To identify the most promising approaches for clinical application.

Main Methods:

  • Review of existing literature on gene therapy for bladder cancer.
  • Analysis of vector structural modifications.
  • Evaluation of promoter modifications in viral vectors.

Related Experiment Videos

  • Assessment of vector administration timing and routes.

    • Main Results:

    • Various modifications improve gene transfer efficiency.
    • Intravesical administration of polyamides with adenoviral vectors demonstrates significant promise.
    • This combined approach shows potential for enhancing therapeutic effects.

    Conclusions:

    • Gene therapy strategies can improve treatment for superficial bladder cancer.
    • Polyamide-adenoviral vector combination is a highly promising approach.
    • This method may supplement or replace current treatment modalities.